China Resources Boya Bio-pharmaceutical Group (SHE:300294) obtained approval from health authorities in the Chinese autonomous region of Inner Mongolia to establish a blood collection station, according to a Shenzhen Stock Exchange filing on Monday.
The Chinese drugmaker will set up the station in Dalate Banner, Ordos City, China, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。